Table 3 Univariate analysis of clinicopathological and immunohistochemical parameters

Gender

1.182 (0.64-2.185)

0.593

1.154 (0.608-2.19)

0.661

Age

1.092 (0.665-1.793)

0.727

1.27 (0.753-2.144)

0.37

Tumor location

Upper

Ref.

0.213

Ref.

0.6

Middle

0.517 (0.2554-1.202)

0.083

0.653 (0.286-1.493)

0.312

Lower

0.553 (0.545-1.608)

0.135

0.698 (0.296-1.65)

0.413

Tumor length

1.172 (0.715-1.923)

0.529

1.343 (0.797-2.262)

0.269

Differential Grade

Well

Ref.

0.095

Ref.

0.17

Moderate

1.947 (1.045-3.629)

0.036

1.881 (0.971-3.645)

0.061

Poor

1.334 (0.666-2.672)

0.417

1.449 (0.697-3.015)

0.321

T stage

T1

Ref.

0.121

Ref.

0.026

T2

1.359 (0.539-3.454)

0.519

1.425 (0.477-4.253)

0.526

T3

1.954 (0.871-4.385)

0.104

2.706 (1.061-6.9)

0.037

T4

3.328 (1.113-9.951)

0.031

4.618 (1.404-15.196)

0.012

LN metastasis

2.506 (1.51-4.157)

<0.001

2.469 (1.455-4.188)

0.001

Positive LN number

0

Ref.

0.001

Ref.

0.002

1

3.479 (1.756-6.89)

<0.001

3.01891.491-6.112

0.002

≥2

2.117 (1.176-3.812)

0.012

2.20391.195-4.063

0.011

pTNM stage

I

Ref.

<0.001

Ref.

<0.001

II

2.03 (0.919-4.482)

0.08

2.334 (0.951-5.729)

0.064

III

4.365 (1.962-9.713)

<0.001

5.254 (2.139-12.91)

<0.001

Treatment regimens

Surgery alone

Ref.

0.081

Ref.

0.063

Adjuvant chemotherapy

0.839 (0.354-1.993)

0.692

0.747 (0.291-1.919)

0.545

Adjuvant radiation

1.821 (0.961-3.451)

0.066

1.99 (1.04-3.807)

0.038

Adjuvant chemoradiation

2.152 (0.992-4.67)

0.053

2.054 (0.902-4.676)

0.086

Immunohistochemical markers

Intratumoral neutrophils

2.505 (1.496-4.196)

<0.001

2.559 (1.487-4.406)

<0.001

Intratumoral CD8+ lymphocytes

0.896 (0.546-1.471)

0.665

0.959 (0.57-1.613)

0.875

Intratumoral NLR

1.279 (0.78-2.097)

0.329

1.316 (0.783-2.214)

0.3

Peritumoral neutrophils

1.035 (0.63-1.7)

0.893

1.119 (0.664-1.886)

0.672

Peritumoral CD8+ lymphocytes

0.952 (0.581-1.561)

0.846

1.032 (0.613-1.735)

0.907

Peritumoral NLR

1.306 (0.788-2.165)

0.3

1.292 (0.761-2.195)

0.343